The Arrhythmias drugs in development market research report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Arrhythmias. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Arrhythmias and features dormant and discontinued products.
GlobalData tracks 25 drugs in development for Arrhythmias by 25 companies/universities/institutes. The top development phase for Arrhythmias is preclinical with 12 drugs in that stage. The Arrhythmias pipeline has 17 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Arrhythmias pipeline products market are: Oregon Health & Science University, Les Laboratoires Servier and University of Sydney.
The key targets in the Arrhythmias pipeline products market include Calcium/Calmodulin Dependent Protein Kinase Type II, Potassium Voltage Gated Channel Subfamily H Member 2, and Ryanodine Receptor 2.
The key mechanisms of action in the Arrhythmias pipeline product include Calcium/Calmodulin Dependent Protein Kinase Type II Inhibitor with three drugs in Preclinical. The Arrhythmias pipeline products include two routes of administration with the top ROA being Oral and seven key molecule types in the Arrhythmias pipeline products market including Small Molecule, and Gene Therapy.
Arrhythmias overview
An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness; fainting or nearly fainting; sweating; shortness of breath; and chest pain. Treatment includes anti-arrhythmics and anticoagulants.
For a complete picture of Arrhythmias’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
